Have a feature idea you'd love to see implemented?
Let us know!
PCRX Pacira BioSciences Inc
Price (delayed)
$17.38
Market cap
$802.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$1.2B
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local
Highlights
Pacira BioSciences's gross profit has increased by 11% YoY
The company's gross margin rose by 6% YoY
The company's quick ratio has shrunk by 67% QoQ and by 49% YoY
The equity has declined by 15% since the previous quarter and by 10% year-on-year
Key stats
What are the main financial stats of PCRX
Market
Valuations
Earnings
Shares outstanding
46.17M
Market cap
$802.49M
Enterprise value
$1.2B
Price to book (P/B)
1.07
Price to sales (P/S)
1.15
EV/EBIT
N/A
EV/EBITDA
33
EV/Sales
1.73
Revenue
$694.96M
EBIT
-$39.64M
EBITDA
$36.39M
Free cash flow
$193.53M
Per share
Balance sheet
Liquidity
EPS
-$1.97
Free cash flow per share
$4.19
Book value per share
$16.25
Revenue per share
$15.06
TBVPS
$23.44
Total assets
$1.52B
Total liabilities
$772.11M
Debt
$644.42M
Equity
$749.58M
Working capital
$383.57M
Debt to equity
0.86
Current ratio
2.25
Quick ratio
1.81
Net debt/EBITDA
10.95
Margins
Efficiency
Dividend
EBITDA margin
5.2%
Gross margin
74.4%
Net margin
-13.1%
Operating margin
-9.3%
Return on assets
-5.7%
Return on equity
-10.7%
Return on invested capital
-3.2%
Return on capital employed
-3.3%
Return on sales
-5.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCRX stock price
How has the Pacira BioSciences stock price performed over time
Intraday
2.06%
1 week
6.17%
1 month
0.29%
1 year
-34.81%
YTD
-48.49%
QTD
15.48%
Financial performance
How have Pacira BioSciences's revenue and profit performed over time
Revenue
$694.96M
Gross profit
$516.72M
Operating income
-$64.91M
Net income
-$90.73M
Gross margin
74.4%
Net margin
-13.1%
The company's operating income has shrunk by 170% QoQ
PCRX's operating margin has shrunk by 169% QoQ
Pacira BioSciences's gross profit has increased by 11% YoY
The company's gross margin rose by 6% YoY
Growth
What is Pacira BioSciences's growth rate over time
Valuation
What is Pacira BioSciences stock price valuation
P/E
N/A
P/B
1.07
P/S
1.15
EV/EBIT
N/A
EV/EBITDA
33
EV/Sales
1.73
PCRX's P/B is 68% below its 5-year quarterly average of 3.3 and 24% below its last 4 quarters average of 1.4
The equity has declined by 15% since the previous quarter and by 10% year-on-year
The price to sales (P/S) is 71% lower than the 5-year quarterly average of 3.9 and 36% lower than the last 4 quarters average of 1.8
The revenue has grown by 4.4% YoY
Efficiency
How efficient is Pacira BioSciences business performance
Pacira BioSciences's return on sales has shrunk by 200% YoY and by 134% QoQ
Pacira BioSciences's ROIC has plunged by 136% from the previous quarter
Dividends
What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCRX.
Financial health
How did Pacira BioSciences financials performed over time
The total assets is 97% greater than the total liabilities
The current ratio has plunged by 67% from the previous quarter and by 53% YoY
The company's quick ratio has shrunk by 67% QoQ and by 49% YoY
Pacira BioSciences's debt is 14% less than its equity
Pacira BioSciences's debt to equity has increased by 21% YoY and by 16% from the previous quarter
The equity has declined by 15% since the previous quarter and by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.